Artwork

Indhold leveret af PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

1:10:47
 
Del
 

Manage episode 307310264 series 9912
Indhold leveret af PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.
  continue reading

411 episoder

Artwork
iconDel
 
Manage episode 307310264 series 9912
Indhold leveret af PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.
  continue reading

411 episoder

Tüm bölümler

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning